Drug · DIN 02458551
PAZEO
Yes: authorized and sold in Canada
Authorized, and the company reports that it sells it in Canada.
Status Marketed since March 12, 2018; first marketed March 12, 2018.
- Drug Identification Number (DIN)
- 02458551
- Company (DIN owner)
- Novartis Pharmaceuticals Canada Inc.Montreal, Quebec, Canada
- Schedule
- Prescription
- Dosage form
- Solution
- Route
- Ophthalmic
- Therapeutic class (ATC)
- Olopatadine S01GX09
- Class
- Human
- Record last updated
- March 22, 2025
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| OLOPATADINE (OLOPATADINE HYDROCHLORIDE) | 0.7 % | W/V |
Notices of Compliance
Health Canada approvals that name this DIN.
- March 17, 2017: NOC 19083New Drug Submission (NDS) · Transfer of drug identification number
- October 28, 2016: NOC 18612New Drug Submission (NDS)